Evaluation the Effect of Topiramate on the Induction Genotoxicity in Obesity Patients

Abstract

Topiramate ( sulfamate - substituted monosaccharide) a weight loss drug used a pharmacotherapeutic agent for obesity , a study was performed to evaluate the effect of the topiramate to induce chromosome aberrations (CA) and sister chromatid exchange (SCE) in lymphocytes of obesity patients . CA and SCE, a sensitive measure of chromosome damage , were counted in peripheral blood lymphocytes from 32 obesity patients treated with topiramate dose ( 6 months with 81mg/day , 12 months with 129 mg/day) and 16 healthy person as control group who had never received topiramate and other drugs during the period of the study. All of the treated patients with topiramate ,have cells with CA and abnormal SCE frequencies, in analysis ,obesity patients, was significantly increased CA in 129mg/day and 81mg/day topiramate dose compared with control ( 4.08±1.51 and 3.56±1.21 ) respectively, vs (1.40± 0.81),(P<0.01).Furthermore, a significantly higher SCE/Cell frequency (10.42 ±0.75and 8.75±0.38) in treated obesity patients with 129 mg/day ,81mg/day dose respectively comparison with their control group (5.91±0.31), (P<0.001).
 The chromosome damage and genotoxics are related to the daily dose and may be determined by the duration of treatment .We conclude the patients treatment with topiramate may be associated with genetic toxicity according to byproducts of drug metabolism.